Back to Annual Meeting

Back to Annual Meeting

Abstract #161632

Jacqueline Payne, JD, Government Relations, Planned Parenthood Federation of America, 1780 Massachusetts Ave, NW, Washington, DC 20036, 202-973-4810, jackie.payne@ppfa.org

Ethical, health and political considerations of new biotechnologies invite reproductive rights advocates to reassess their positions around privacy and individual autonomy. Many politicians and bioethicists are engaging in public debate by simply applying their positions on abortion, yet the pro-choice/pro-life framework is not expansive enough to encompass the complex issues presented by these technologies. At the same time that the moral status of the embryo and abortion politics have dominated public discussion, decision-makers have neglected to bring reproductive rights advocates to the table. To ensure that upcoming policy proposals reflect their concerns, reproductive rights advocates have recently begun to engage in discussion about these technologies, developing a new set of principles based on human rights and social justice. This presentation will cover current political discussions within the reproductive rights movement related to new biotechnologies and the importance of using a reproductive justice analysis to advance the health, well-being, and rights of women.

Learning Objectives: At the end of this session, participants will be able to

• Articulate a reproductive justice perspective of the ethical, health and political considerations of new biotechnologies
• Understand the current political debate within the reproductive rights movement regarding new biotechnologies
• Understand the importance of using a reproductive justice model to promote the health and rights of women

Keywords: Reproductive Health, Genetics

Related Web page: ppfa.org/

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.